Pluri Inc. Cost, Direct Material
Pluri Inc. (PLUR) reported Cost, Direct Material of $1.53 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostDirectMaterial · last filed 2026-09-10
- Pluri Inc. cost, direct material for the quarter ending 2026-06-30 was $237.00K, a 59.21% decline year-over-year.
- Pluri Inc. cost, direct material for the quarter ending 2026-03-31 was $356.00K, a 15.24% decline year-over-year.
- Pluri Inc. cost, direct material for the quarter ending 2025-12-31 was $497.00K, a 82.05% increase year-over-year.
- Pluri Inc. cost, direct material for the quarter ending 2025-09-30 was $436.00K.
- Pluri Inc. cost, direct material for fiscal 2026 was $1.53M, a 20.48% decline from fiscal 2025.
- Pluri Inc. cost, direct material for fiscal 2025 was $1.92M.
| Period end | Cost, Direct Material 3 month | Cost, Direct Material 6 month | Cost, Direct Material 9 month | Cost, Direct Material 12 month |
|---|---|---|---|---|
| 2026-06-30 | $237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-10 | $593.00K derived: sum of 2 quarters · filed 2026-09-10 | $1.09M derived: sum of 3 quarters · filed 2026-09-10 | $1.53M 10-K · filed 2026-09-10 |
| 2026-03-31 | $356.00K 10-Q · filed 2026-05-14 | $853.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.29M 10-Q · filed 2026-05-14 | $1.87M derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-12-31 | $497.00K 10-Q · filed 2026-02-12 | $933.00K 10-Q · filed 2026-02-12 | $1.51M derived: sum of 3 quarters · filed 2026-09-10 | $1.93M derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-09-30 | $436.00K derived: 10-K 12 month − 3 quarters · filed 2026-09-10 | $1.02M derived: sum of 2 quarters · filed 2026-09-10 | $1.44M derived: sum of 3 quarters · filed 2026-09-10 | $1.71M derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-06-30 | $581.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-10 | $1.00M derived: sum of 2 quarters · filed 2026-09-10 | $1.27M derived: sum of 3 quarters · filed 2026-09-10 | $1.92M 10-K · filed 2026-09-10 |
| 2025-03-31 | $420.00K 10-Q · filed 2026-05-14 | $693.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.34M 10-Q · filed 2026-05-14 | |
| 2024-12-31 | $273.00K 10-Q · filed 2026-02-12 | $918.00K 10-Q · filed 2026-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |